Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
0.6088
-0.0182 (-2.90%)
At close: Dec 12, 2025, 4:00 PM EST
0.5900
-0.0188 (-3.09%)
After-hours: Dec 12, 2025, 7:57 PM EST
Longeveron Employees
Longeveron had 25 employees as of December 31, 2024. The number of employees increased by 1 or 4.17% compared to the previous year.
Employees
25
Change (1Y)
1
Growth (1Y)
4.17%
Revenue / Employee
$57,480
Profits / Employee
-$853,640
Market Cap
12.99M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25 | 1 | 4.17% |
| Dec 31, 2023 | 24 | 3 | 14.29% |
| Dec 31, 2022 | 21 | 1 | 5.00% |
| Dec 31, 2021 | 20 | 8 | 66.67% |
| Dec 31, 2020 | 12 | -4 | -25.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LGVN News
- 11 days ago - Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging - GlobeNewsWire
- 11 days ago - Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer's Disease Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025) - GlobeNewsWire
- 24 days ago - Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025) - GlobeNewsWire
- 4 weeks ago - Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy - GlobeNewsWire
- 5 weeks ago - Longeveron Inc. (LGVN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect - GlobeNewsWire
- 2 months ago - Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference - GlobeNewsWire
- 2 months ago - Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa - GlobeNewsWire